natgillin/translations-raw huggingface dataset:
− if you have or have had severe kidney or liver problems.
− če imate ali ste kdaj imeli hude težave z ledvicami ali jetri;
(> 1 mm),
p < 0,001).
Pharmacotherapeutic group: Antithrombotic agent (platelet aggregation inhibitors excl. heparin), ATC code: B01AC16
Farmakoterapevtska skupina: Antitrombotična zdravila (zaviralci agregacije trombocitov z izjemo heparina), ATC oznaka: B01AC16
Thrombocytopaenia occurring after first exposure to a GPIIb/IIIa inhibitor may be explained by the fact that antibodies are naturally present in some normal individuals.
Trombocitopenijo, ki se pojavi po prvi izpostavljenosti zaviralcu GPIIb/IIIa, se lahko pojasni s tem, da so protitelesa pri nekaterih zdravih osebah naravno prisotna.
Bleeding events were more frequent in patients receiving concurrent heparin while undergoing PCI, when ACT exceeded 350 seconds (see section 4.4, heparin use).
Krvavitve so bile pogostejše pri bolnikih, ki so med perkutano koronarno intervencijo sočasno dobivali heparin, če je AČS presegal 350 sekund (glejte poglavje 4.4,
Incidence of Death/CEC-Assessed MI («Treated as Randomised» Population)
Incidenca smrti oz. MI po oceni KKP (populacija “zdravljena v skladu z razporeditvijo v skupine”)
In the subgroup of patients undergoing PCI, major bleeding was observed commonly, in 9.7 % of Integrilin-treated patients vs. 4.6 % of placebo-treated patients.
podskupini bolnikov, ki so jim naredili perkutano koronarno intervencijo, so bile večje krvavitve pogoste: pojavile so se pri 9,7 % zdravljenih z zdravilom Integrilin in 4,6 % prejemnikov placeba.
If percutaneous coronary intervention (PCI) is performed during Integrilin therapy, the intravenous solution may be continued for up to 96 hours.
Če je bil med zdravljenjem z zdravilom Integrilin opravljen perkutani koronarni poseg (PCI), lahko intravenska infuzija traja do 96 ur.
− raised cardiac enzymes or markers (e.g. CK-MB, troponins) and
- zvišanjem vrednosti srčnih encimov ali markerjev (npr. CK-MB, troponini), - srčnim popuščanjem.
What Integrilin looks like and contents of the pack Integrilin solution for infusion: 100 ml vial, pack of one vial.
Izgled zdravila Integrilin in vsebina pakiranja Integrilin raztopina za infundiranje: 100 ml viala, pakiranje po ena viala.
Take special care with Integrilin:
Bodite posebno pozorni pri uporabi zdravila Integrilin
4.4 Special warnings and precautions for use
4.4 Posebna opozorila in previdnostni ukrepi Krvavitve
The infusion was continued until hospital discharge, until the time of coronary artery bypass grafting (CABG) or for up to 72 hours, whichever occurred first.
Infuzijo so prejemali do odpusta iz bolnišnice, do koronarnega premostitvenega posega ali do preteka 72 ur, karkoli je nastopilo prej.
OTHER SPECIAL WARNING(S), IF NECESSARY Inspect the vial content.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
To avoid the possibility of interactions with other medicines please tell your doctor or hospital pharmacist if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription.
Druga zdravila in zdravilo Integrilin Da bi se izognili morebitnemu medsebojnemu delovanju z drugimi zdravili, obvestite svojega zdravnika ali bolnišničnega farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli zdravilo, tudi če ste ga dobili brez recepta.
INTEGRILIN is compatible with 0.9 % sodium chloride solution for injection and with dextrose 5 % in Normosol R with or without potassium chloride.
Zdravilo INTEGRILIN je združljivo z 0,9 % raztopino natrijevega klorida za injiciranje in s 5 % dekstrozo v Normosolu R, z ali brez kalijevega klorida.
If the patient weighs < 70 kg, a bolus dose of 60 units/kg is recommended, followed by an infusion of 12 units/kg/hr.
Če pa je bolnikova telesna masa < 70 kg, uporabite bolusni odmerek 60 enot/kg, ki naj mu sledi infuzija 12 enot/kg/h.
Marketing Authorisation Holder and manufacturer Marketing Authorisation Holder:
Imetnik dovoljenja za promet z zdravilom in izdelovalec Imetnik dovoljenja za promet z zdravilom:
INTEGRILIN is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.
Zdravilo INTEGRILIN je indicirano za preprečevanje zgodnjega miokardnega infarkta pri odraslih z nestabilno angino pektoris ali miokardnim infarktom brez zobca Q v elektrokardiogramu (EKG), ki so imeli zadnji napad bolečine v prsih v preteklih 24 urah ter imajo EKG spremembe, zvišano koncentracijo srčnih encimov ali oboje.
INTEGRILIN is compatible with 0.9 % sodium chloride solution for infusion and with dextrose 5 % in Normosol R with or without potassium chloride.
Zdravilo INTEGRILIN je združljivo z 0,9 % raztopino natrijevega klorida za infundiranje in s 5 % dekstrozo v Normosolu R, z ali brez kalijevega klorida.
There is limited therapeutic experience with INTEGRILIN in patients for whom thrombolytic therapy is generally indicated (e.g. acute transmural myocardial infarction with new pathological Q-waves or elevated ST-segments or left bundle branch block in the ECG).
Terapevtske izkušnje z uporabo zdravila INTEGRILIN so skope pri bolnikih, pri katerih je praviloma indicirano trombolitično zdravljenje (npr. tistih z akutnim transmuralnim miokardnim infarktom z novimi patološkimi zobci Q, zvišanjem spojnice ST ali levokračnim blokom v EKG).
Thrombocytopenia and Immunogencity related to GP IIb/IIIa inhibitors INTEGRILIN inhibits platelet aggregation, but does not appear to affect the viability of platelets.
Trombocitopenija in imunogenost, povezani z zaviralci GP IIb/IIIa Zdravilo INTEGRILIN zavira agregacijo trombocitov, ni pa videti, da bi vplival na njihovo življenjsko dobo.
LIST OF EXCIPIENTS Citric acid monohydrate, sodium hydroxide, water for injections.
SEZNAM POMOŽNIH SNOVI citronska kislina monohidrat, natrijev hidroksid in voda za injekcije.
The incidence of severe or life threatening bleeding events with Integrilin was 1.9% compared to 1.1% with placebo.
Incidenca hudih ali smrtno nevarnih krvavitev je bila med uporabo zdravila Integrilin 1,9 % in med uporabo placeba 1,1 %.
In patients with moderate to severe renal insufficiency (creatinine clearance < 50 ml/min), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels are approximately doubled.
Pri bolnikih z zmerno do hudo ledvično insuficienco (kreatininski očistek < 50 ml/min) je očistek eptifibatida za približno 50 % manjši, plazemske koncentracije v stanju dinamičnega ravnovesja pa so približno podvojene.
GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland Manufacturer:
GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Irska Izdelovalec:
What Integrilin contains
Kaj vsebuje zdravilo Integrilin
− history of stroke within 30 days or any history of haemorrhagic stroke
- anamnezo možganske kapi v zadnjih 30 dneh ali anamnezo hemoragične kapi kadarkoli;
Before infusion of INTEGRILIN, the following laboratory tests are recommended to identify preexisting haemostatic abnormalities: prothrombin time (PT) and aPTT, serum creatinine, platelet count, haemoglobin and haematocrit levels.
Za ugotavljanje obstoječih motenj hemostaze je pred začetkom infuzije zdravila INTEGRILIN priporočljivo opraviti naslednje laboratorijske preiskave: določanje protrombinskega časa (PČ) in aPTČ, kreatinina v serumu, števila trombocitov ter koncentracije hemoglobina in hematokrita.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 1 vial of 10 ml
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 1 viala 10 ml
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 1 vial of 100 ml
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 1 viala 100 ml
Fatal bleeding (the majority involved central and peripheral nervous system disorders: cerebral or intracranial haemorrhages); pulmonary haemorrhage, acute profound thrombocytopenia, haematoma.
Zelo redki smrtne krvavitve (večinoma je šlo za motnje osrednjega in perifernega živčevja: možganske ali intrakranialne krvavitve), pljučne krvavitve, akutna huda trombocitopenija, hematomi Bolezni imunskega sistema Zelo redki anafilaktične reakcije
MARKETING AUTHORISATION HOLDER
Izkušnje po pridobitvi dovoljenja za promet
In patients undergoing CABG, the incidence of bleeding was not increased by Integrilin compared to the patients treated with placebo.
Pri bolnikih z obvodom koronarne arterije incidenca krvavitev med uporabo zdravila Integrilin ni bila večja kot med uporabo placeba.
Integrilin is given into the vein by direct injection followed by an infusion (drip solution).
Kako uporabljati zdravilo Integrilin Zdravilo Integrilin se daje z injekcijo v veno, temu pa sledi (kapalna) infuzija.
These plasma concentrations are achieved rapidly when the infusion is preceded by a 180 microgram/kg bolus.
Plazemsko koncentracijo v tem območju lahko dosežete hitro, če pred infuzijo uporabite bolus 180 mikrogramov/kg.
GUSTO moderate or severe/life threatening bleeding occurred significantly more often with early routine eptifibatide (7.4% vs. 5.0% in delayed provisional eptifibatide group; p <0.001).
Hude/smrtno nevarne krvavitve po GUSTO so se pojavile značilno pogosteje med zgodnjo rutinsko uporabo eptifibatida (7,4 % v prim.
In patients with moderate renal impairment, (creatinine clearance 30 - 50mL/min) 100% inhibition was achieved at 24 hours following administration of 2 microgram/kg/min.
Pri bolnikih z zmerno okvaro ledvic (kreatininski očistek od 30 do 50 ml/min) je bila 100 % inhibicija dosežena 24 ur po uporabi 2 mikrograma/kg/min.
Integrilin should not be used if it is noticed that particulate matter or discoloration is present.
Ne uporabljajte zdravila Integrilin, če ste opazili delce ali obarvanje vsebine.
− serious bleeding (for example, bleeding inside the abdomen, inside the brain, and into the lungs).
- hude krvavitve (na primer, krvavitve v trebušni votlini, možganih ali v pljuča);
Protection of INTEGRILIN solution from light is not necessary during administration.
Zaščita raztopine Integrilin pred svetlobo med uporabo ni potrebna.
Arterial sheaths may be removed when coagulation has returned to normal (e.g. when activated clotting time (ACT) is less than 180 seconds (usually 26 hours after discontinuation of heparin).
ko je aktivirani čas strjevanja (AČS) manjši od 180 sekund; ponavadi 2 do 6 ur po ukinitvi heparina).
Keep this medicine out of the sight and reach of children Do not use this medicine after the expiry date (EXP) stated on the package and the vial.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na viali poleg oznake »EXP«.
INTEGRILIN is intended for use with acetylsalicylic acid and unfractionated heparin.
4.1 Terapevtske indikacije Zdravilo INTEGRILIN je namenjeno uporabi z acetilsalicilno kislino in nefrakcioniranim heparinom.
Early routine eptifibatide in this high-risk NSTE-ACS optimally-treated population who were managed with an invasive strategy did not result in a statistically significant reduction in the composite primary endpoint of rate of death, MI, RI-UR, and TBO within 96 hours compared with a regimen of delayed provisional eptifibatide (9.3% in early eptifibatide patients vs. 10.0% in patients assigned to delayed provisional eptifibatide; odds ratio=0.920; 95% CI=0.802-1.055; p=0.234).
UR) in reševanja tromboze (TBO)) v 96 urah v primerjavi s shemo odložene pomožne uporabe eptifibatida (9,3 % med bolniki z zgodnjo uporabo eptifibatida v primerjavi z 10,0 % med bolniki z odloženo pomožno uporabo; razmerje obetov = 0,920, 95% IZ = 0,802-1,055, p = 0,234).
Very common Bleeding (major and minor bleeding including femoral artery access, CABG
Zelo pogosti krvavitve (večje ali manjše krvavitve, vključujoč femoralni arterijski dostop, v povezavi s CABG, v prebavilih, v sečilih in spolnih organih, retroperitonealno,
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Irska 12.
− evidence of gastrointestinal bleeding, gross genitourinary bleeding or other active abnormal bleeding within the previous 30 days of treatment
- preobčutljivostjo na zdravilno učinkovino ali katerokoli pomožno snov navedeno v poglavju - znaki krvavitve v prebavilih, obilno krvavitvijo v sečilih ali spolnih organih ali kako drugo aktivno nenormalno krvavitvijo, ki nastopi v zadnjih 30 dneh pred zdravljenjem;
Shock, hypotension, phlebitis.
Žilne bolezni Pogosti šok, hipotenzija, flebitis
How to store Integrilin
Shranjevanje zdravila Integrilin
Similar differences were noted for TIMI major haemorrhage (118 [2.5%] in early routine use vs. 83 [1.8%] in delayed provisional use; p=0.016).
s 83 [1,8 %] med odloženo pomožno uporabo, p = 0,016).
TIMI major bleeding occurred in 2.7 % of patients who received a reduced dose (1microgram/kg/min) vs 4.2% of patients who received the standard dose (2microgram/kg/min) when eptifibatide was administered in the early routine fashion (p=0.36).
Večje krvavitve po TIMI so se pojavile pri 2,7 % prejemnikov nižjega odmerka (1 mikrogram/kg/min) in pri 4,2 % prejemnikov standardnega odmerka (2 mikrograma/kg/min), če je bil eptifibatid uporabljen v zgodnjem rutinskem načinu (p = 0,36).
In patients with severe renal impairment (creatinine clearance <30mL/min) administered 1microgram/kg/min , 80% inhibition was achieved in more than 80% of patients at 24 hours.
Pri bolnikih s hudo okvaro ledvic (kreatininski očistek < 30 ml/min), ki so prejeli 1 mikrogram/kg/min, je bila 80 % inhibicija po 24 urah dosežena pri več kot 80 % bolnikov.
Not relevant, as INTEGRILIN is intended for use only in hospitalised patients.
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Podatek ni potreben, ker je zdravilo INTEGRILIN namenjeno samo zdravljenju hospitaliziranih bolnikov.
Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, 4.2)
Predpisovanje in izdaja zdravila je le s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
With delayed provisional eptifibatide administration, the TIMI major events were 1.4% vs 2.0% in patients who received reduced dose and standard dose respectively (p=0.54).
V primeru odložene pomožne uporabe eptifibatida je bil delež večjih dogodkov po TIMI med prejemniki nižjega odmerka 1,4 % in med prejemniki standardnega odmerka 2 % (p = 0,54).
− elevated heart rate or blood pressure
- zvišano srčno frekvenco ali krvnim tlakom, - trdovratno ali ponavljajočo se ishemično srčno bolečino,
haematuria, oral/oropharyngeal, haemoglobin/haematocrit decreased and other).
intrakranialno, hematemezo, hematurijo, oralno ali orofaringealno, zmanjšane vrednosti hemoglobina in hematokrita in druge)
Physical and chemical compatibility testing indicate that INTEGRILIN may be administered through an intravenous line with atropine sulfate, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, tissue plasminogen activator, or verapamil.
dajete po intravenski liniji skupaj z atropinijevim sulfatom, dobutaminom, heparinom, lidokainom, meperidinom, metoprololom, midazolamom, morfinom, nitroglicerinom, tkivnim aktivatorjem plazminogena in verapamilom.
Marketing Authorisation Holder:
Navodilo vsebuje:
What you need to know before you are given Integrilin
Kaj morate vedeti, preden boste dobili zdravilo Integrilin Zdravila Integrilin ne smete dobiti:
The primary endpoint event rate was 11.9 % in patients who received a reduced dose (1microgram/kg/min) vs 11.2% in patients who received the standard dose (2microgram/kg/min) when eptifibatide was administered in the early routine fashion (p=0.81).
Delež primarnih opazovanih dogodkov je bil 11,9 % pri prejemnikih nižjega odmerka (1 mikrogram/kg/min) in 11,2 % pri prejemnikih standardnega odmerka (2 mikrograma/kg/min), če je bil eptifibatid uporabljen v zgodnjem rutinskem načinu (p = 0,81).
With delayed provisional eptifibatide administration, the event rates were 10% vs 11.5% in patients who received reduced dose and standard dose respectively (p=0.61).
V primeru odložene pomožne uporabe eptifibatida pa je bil delež dogodkov med prejemniki nižjega odmerka 10 % in med prejemniki standardnega odmerka 11,5 % (p = 0,61).
INTEGRILIN solution for infusion must be used in conjunction with INTEGRILIN solution for injection.
Raztopino za infundiranje INTEGRILIN morate uporabljati skupaj z raztopino za injiciranje INTEGRILIN.
INTEGRILIN must not be used to treat patients with:
4.3 Kontraindikacije Z zdravilom INTEGRILIN ne smete zdraviti bolnikov z/s:
72 hours, until initiation of coronary artery bypass graft (CABG) surgery, or until discharge from the hospital (whichever occurs first).
Zdravljenje naj se nadaljuje s kontinuirano infuzijo 2 mikrograma/kg/min do 72 ur, bodisi do začetka koronarnega premostitvenega posega (CABG - Coronary Artery Bypass Graft) ali do odpusta iz bolnišnice (karkoli nastopi prej).
− heart failure
Srčne bolezni
Data are limited on the use of INTEGRILIN in patients receiving thrombolytic agents.
Zdravilo INTEGRILIN in trombolitična zdravila Podatki o uporabi zdravila INTEGRILIN pri bolnikih, zdravljenih s trombolitičnimi zdravili, so omejeni.
Integrilin 2 mg/ml solution for injection eptifibatide
INTEGRILIN 2 mg/ml raztopina za injiciranje eptifibatid
INTEGRILIN solution for injection must be used in conjunction with INTEGRILIN solution for infusion.
Raztopino za injiciranje INTEGRILIN morate uporabljati skupaj z raztopino za infundiranje INTEGRILIN.
Each ml of solution for injection contains 2 mg of eptifibatide.
Vsak ml raztopine za injiciranje vsebuje 2 mg eptifibatida.
An increased risk of bleeding may also be observed in patients who receive early administration of INTEGRILIN (e.g. upon diagnosis) compared to receiving it immediately prior to PCI, as seen in the Early ACS trial.
(npr. ob postavitvi diagnoze), v primerjavi s tistimi, ki ga prejmejo tik pred perkutanim koronarnim posegom, kot je pokazala študija Early ACS.
− skin rash (such as hives).
- kožni izpuščaj (kot je koprivnica);
Because INTEGRILIN inhibits platelet aggregation, caution must be employed when it is used with other medicinal products that affect haemostasis, including ticlopidine, clopidogrel, thrombolytics, oral anticoagulants, dextran solutions, adenosine, sulfinpyrazone, prostacyclin, non-steroidal antiinflammatory agents, or dypyridamole (see section 4.5).
peroralnimi antikoagulanti, raztopinami dekstrana, adenozinom, sulfinpirazonom, prostaciklinom, nesteroidnimi protivnetnimi zdravili ali dipiridamolom (glejte poglavje 4.5).
Uncommon Cerebral ischaemia.
Bolezni živčevja Občasni možganska ishemija
Vascular Disorders Common
Občasni trombocitopenija
Integrilin 0.75 mg/ml solution for infusion eptifibatide
INTEGRILIN 0,75 mg/ml raztopina za infundiranje eptifibatid
Patients most likely to benefit from INTEGRILIN treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty) (see section 5.1).
Verjetnost, da bo zdravljenje z zdravilom INTEGRILIN koristilo bolniku, je največja pri bolnikih z velikim tveganjem za nastanek miokardnega infarkta v prvih 3 do 4 dneh po pojavu akutnih simptomov angine pektoris.
NAME OF THE MEDICINAL PRODUCT INTEGRILIN 2 mg/ml solution for injection
IME ZDRAVILA INTEGRILIN 2 mg/ml, raztopina za injiciranje
− major surgery or severe trauma within past 6 weeks
- večjo operacijo ali hujšo poškodbo v zadnjih 6 tednih; - hemoragično diatezo v anamnezi;
There is no experience with INTEGRILIN and low molecular weight heparins.
Izkušenj s sočasno uporabo nizkomolekularnih heparinov in zdravila INTEGRILIN ni.
Skin and subcutaneous tissue disorders Very rare
Bolezni kože in podkožja Zelo redki težave na mestu aplikacije npr. urtikarija
Each ml of solution for infusion contains 0.75 mg of eptifibatide.
Vsak ml raztopine za injiciranje vsebuje 0,75 mg eptifibatida.
INTEGRILIN is an antithrombotic agent that acts by inhibition of platelet aggregation; therefore the patient must be observed carefully for indications of bleeding during treatment (see section 4.8).
Bolnika morate torej med zdravljenjem skrbno spremljati, da odkrijete znake krvavitve (glejte poglavje 4.8).
If you have any further questions on the use of this product, ask your doctor or hospital pharmacist or nurse.
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom, z bolnišničnim farmacevtom ali z medicinsko sestro.
What Integrilin looks like and contents of the pack Integrilin solution for injection: 10 ml vial, pack of one vial.
Integrilin raztopina za injiciranje: 10 ml viala, pakiranje po ena viala.
If Percutaneous Coronary Intervention (PCI) is performed during eptifibatide therapy, continue the infusion for 20-24 hours post-PCI for an overall maximum duration of therapy of 96 hours.
Percutaneous Coronary Intervention), morate nato z infuzijo nadaljevati še 20 do 24 ur po perkutanemkoronarnem posegu; povprečno najdaljše skupno trajanje zdravljenja je 96 ur.
NAME OF THE MEDICINAL PRODUCT INTEGRILIN 0.75 mg/ml solution for infusion
IME ZDRAVILA INTEGRILIN 0,75 mg/ml raztopina za infundiranje
Major bleeding was also very common and reported more frequently with Integrilin than with placebo in the PURSUIT study (>1/10 or 10.8% versus 9.3%), but it was infrequent in the vast majority of patients who did not undergo CABG within 30 days of inclusion in the study.
10,8 % v primerjavi z 9,3 %), a niso bile pogoste pri veliki večini bolnikov, pri katerih ni bil narejen obvod koronarne arterije v 30 dneh od vključitve v študijo.
• either ST-segment changes: ST depression > 0.5 mm of less than 30 minutes or persistent ST
• bodisi spremembe spojnice ST: znižanje spojnice ST za > 0,5 mm za manj kot 30 minut ali trdovratno zvišanje spojnice ST za > 0,5 mm, ki ni zahtevalo reperfuzijske terapije ali trombolitičnih zdravil, inverzijo vala T (> 1 mm), • ali povečanje vrednosti CK-MB.
The pivotal clinical trial for Unstable Angina (UA)/Non-Q Wave Myocardial Infarction (NQMI) was PURSUIT.
Osrednja klinična študija nestabilne angine pektoris ali miokardnega infarkta brez zobca Q v EKG je bila študija PURSUIT.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION INTEGRILIN 0.75 mg/ml solution for infusion eptifibatide
IME ZDRAVILA IN POT(I) UPORABE INTEGRILIN 0,75 mg/ml raztopina za infundiranje eptifibatid intravenska uporaba
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION INTEGRILIN 2 mg/ml solution for injection eptifibatide
IME ZDRAVILA IN POT(I) UPORABE INTEGRILIN 2 mg/ml raztopina za injiciranje eptifibatid intravenska uporaba
Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive ligands to the glycoprotein (GP)IIb/IIIa receptors.
Willebrandovega faktorja in drugih adhezivnih ligandov na receptorje glikoproteina (GP) IIb/IIIa.
− medicines that prevent blood clots, including warfarin, dipyridamole, ticlopidine, aspirin (except those that you may be given as part of Integrilin treatment).
tiklopidinom in acetilsalicilno kislino (razen tistih, ki jih boste morda dobili v okviru zdravljenja z zdravilom Integrilin).
− If you have any further questions, ask your doctor or hospital pharmacist or nurse.
- Če imate dodatna vprašanja, se posvetujte s svojim zdravnikom, z bolnišničnim farmacevtom ali z medicinsko sestro.
PURSUIT: This was a randomised, double-blind evaluation of the efficacy and safety of Integrilin versus placebo for reducing mortality and myocardial (re)infarction in patients with unstable angina or non-Q-wave myocardial infarction.
Integrilin v primerjavi s placebom za zmanjšanje umrljivosti in (ponovnega) miokardnega infarkta pri bolnikih z nestabilno angino pektoris ali miokardnim infarktom brez zobca Q v EKG.